Power considerations for clinical trials using multivariate time-to-event data

被引:0
|
作者
Hughes, MD [1 ]
机构
[1] HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115
关键词
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many clinical trials involve the collection of data on the times to occurrence of different types of events, such as different fungal infections in AIDS research, or of recurrences of the same type, such as successive fits in epilepsy research. The multivariate proportional hazards model allows for analysis of this data and software for doing this is now widely available. In this paper, the approximate power of a clinical trial that aims to use such data for comparing two treatments is derived. Special attention is given to the bivariate case, both to show that the approximation works well and to illustrate how various design parameters affect the power of a trial. As with any multivariate data in clinical trials, there are many conceptual issues that should be considered during trial design; the paper closes with a discussion of some of these. (C) 1997 by John Wiley & Sons, Ltd. Stat. Med., Vol. 16, 865-882 (1997).
引用
收藏
页码:865 / 882
页数:18
相关论文
共 50 条
  • [41] Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
    Rulli, Eliana
    Ghilotti, Francesca
    Biagioli, Elena
    Porcu, Luca
    Marabese, Mirko
    D'Incalci, Maurizio
    Bellocco, Rino
    Torri, Valter
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (12) : 1456 - 1463
  • [42] Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
    Li, Yimei
    Hwang, Wei-Ting
    Maude, Shannon L.
    Teachey, David T.
    Frey, Noelle V.
    Myers, Regina M.
    Leahy, Allison Barz
    Liu, Hongyan
    Porter, David L.
    Grupp, Stephan A.
    Shaw, Pamela A.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (18) : 3940 - 3949
  • [43] Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution
    Waleed, Muhammad
    He, Jianghua
    Phadnis, Milind A.
    [J]. PHARMACEUTICAL STATISTICS, 2021, 20 (03) : 610 - 644
  • [44] Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls
    Pocock, SJ
    Clayton, TC
    Altman, DG
    [J]. LANCET, 2002, 359 (9318): : 1686 - 1689
  • [45] The net benefit for time-to-event outcome in oncology clinical trials with treatment switching
    Fukuda, Musashi
    Sakamaki, Kentaro
    Oba, Koji
    [J]. CLINICAL TRIALS, 2023, 20 (06) : 670 - 680
  • [46] Non-inferiority trials with time-to-event data: clarifying the impact of censoring
    Choi, Jaeun
    Xue, Xiaonan
    Kim, Mimi
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024, 34 (02) : 222 - 239
  • [47] Sample size estimation for non-inferiority trials of time-to-event data
    Crisp, Adam
    Curtis, Paula
    [J]. PHARMACEUTICAL STATISTICS, 2008, 7 (04) : 236 - 244
  • [48] A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome
    Royston, Patrick
    [J]. STATA JOURNAL, 2017, 17 (02): : 405 - 421
  • [49] Aligning sample size calculations with estimands in clinical trials with time-to-event outcomes
    Fang, Yixin
    Jin, Man
    Wu, Chengqing
    [J]. STATISTICS AND ITS INTERFACE, 2024, 17 (01) : 63 - 68
  • [50] Power and sample-size analysis for the Royston Parmar combined test in clinical trials with a time-to-event outcome
    Royston, Patrick
    [J]. STATA JOURNAL, 2018, 18 (01): : 3 - 21